AMPICILLIN AND SULBACTAM

Post-LOE

ampicillin sodium; sulbactam sodium

Hikma

ANDAINJECTIONINJECTABLE

Approved

Mar 2002

Lifecycle

Post-LOE

Competitive Pressure

30/100

Data completeness

3/8 — Basic

AMPICILLIN AND SULBACTAM (ampicillin sodium; sulbactam sodium) by Hikma is clinical pharmacology general immediately after completion of a 15-minute intravenous infusion of ampicillin and sulbactam, peak serum concentrations of ampicillin and sulbactam are attained. Approved for infections due to susceptible strains of the designated microorganisms in the conditions listed below, development of drug-resistant bacteria, maintain effectiveness of ampicillin and 5 more indications. First approved in 2002.

Drug data last refreshed 19h ago

Mechanism of Action

CLINICAL PHARMACOLOGY General Immediately after completion of a 15-minute intravenous infusion of ampicillin and sulbactam, peak serum concentrations of ampicillin and sulbactam are attained. Ampicillin serum levels are similar to those produced by the administration of equivalent amounts of…

Worked on AMPICILLIN AND SULBACTAM at Hikma? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

AMPICILLIN AND SULBACTAM

Mechanism of Action

Indications (8)